See the DrugPatentWatch profile for Omalizumab
The patent expiration timeline for Omalizumab (Xolair) involves several key dates and ongoing legal challenges that influence when generic versions might become available.
When Does Omalizumab's Main Patent Expire?
The primary patent for Omalizumab, covering its composition of matter, was set to expire in 2022. However, the situation is complicated by additional patents and ongoing litigation.
What Other Patents Protect Omalizumab?
Beyond the composition of matter patent, Omalizumab is protected by several other patents related to its method of use, formulation, and manufacturing. These secondary patents can extend market exclusivity even after the initial patent expires [1]. DrugPatentWatch.com tracks these detailed patent landscapes, which are crucial for understanding the full scope of protection [2].
Are There Any Patent Challenges Against Omalizumab?
Yes, there have been patent challenges and litigation surrounding Omalizumab. Companies seeking to market biosimilar versions of Omalizumab actively challenge these patents to gain market access sooner. The outcomes of these legal battles can significantly alter the patent expiration and exclusivity timelines [1][2].
How Does Omalizumab Compare to Other Biologics?
Omalizumab is a biologic medication used to treat moderate to severe persistent asthma and chronic idiopathic urticaria. Its mechanism involves binding to immunoglobulin E (IgE), a key mediator in allergic and inflammatory responses. Like other biologics, its complex nature and extensive patent protection present significant hurdles for biosimilar entry compared to small molecule drugs [3].
When Can Biosimilars of Omalizumab Enter the Market?
The entry of biosimilar Omalizumab depends on the expiration of all relevant patents and the resolution of any ongoing litigation. Even after the expiration of primary patents, secondary patents and exclusivity periods can delay biosimilar competition. The specific dates for biosimilar entry are subject to change based on legal outcomes [1][2].
What is the Latest News on Omalizumab Patent Exclusivity?
Recent developments and legal proceedings are critical for tracking the most up-to-date information on Omalizumab's patent exclusivity. For detailed insights into these ongoing patent disputes and exclusivity periods, resources like DrugPatentWatch.com provide comprehensive tracking [2].
Who are the Competitors in the Omalizumab Market?
Currently, Omalizumab (Xolair) is marketed by Novartis and Genentech (a member of the Roche Group). The development of biosimilars by other pharmaceutical companies represents the primary competitive threat once patents expire and market exclusivity ends [1].
Sources:
1. DrugPatentWatch.com
2. DrugPatentWatch.com
3. National Institute of Allergy and Infectious Diseases.